HK1056195B - Codon-optimized papilloma virus sequences - Google Patents
Codon-optimized papilloma virus sequences Download PDFInfo
- Publication number
- HK1056195B HK1056195B HK03106686.3A HK03106686A HK1056195B HK 1056195 B HK1056195 B HK 1056195B HK 03106686 A HK03106686 A HK 03106686A HK 1056195 B HK1056195 B HK 1056195B
- Authority
- HK
- Hong Kong
- Prior art keywords
- hpv
- polynucleotide sequence
- polynucleotide
- cells
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0017990.3A GB0017990D0 (en) | 2000-07-21 | 2000-07-21 | Papilloma virus sequences |
| GB0017990.3 | 2000-07-21 | ||
| GB0025802A GB0025802D0 (en) | 2000-10-20 | 2000-10-20 | Papilloma virus sequences |
| GB0025802.0 | 2000-10-20 | ||
| PCT/GB2001/003290 WO2002008435A1 (en) | 2000-07-21 | 2001-07-20 | Codon-optimized papilloma virus sequences |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1056195A1 HK1056195A1 (en) | 2004-02-06 |
| HK1056195B true HK1056195B (en) | 2007-06-22 |
Family
ID=26244703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK03106686.3A HK1056195B (en) | 2000-07-21 | 2001-07-20 | Codon-optimized papilloma virus sequences |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1301614B1 (enExample) |
| JP (1) | JP2004504057A (enExample) |
| KR (1) | KR100874552B1 (enExample) |
| CN (1) | CN1262665C (enExample) |
| AT (1) | ATE346947T1 (enExample) |
| AU (2) | AU7569501A (enExample) |
| BR (1) | BR0112637A (enExample) |
| CA (1) | CA2416488A1 (enExample) |
| CY (1) | CY1106334T1 (enExample) |
| CZ (1) | CZ2003180A3 (enExample) |
| DE (1) | DE60124918T2 (enExample) |
| DK (1) | DK1301614T3 (enExample) |
| ES (1) | ES2277605T3 (enExample) |
| HK (1) | HK1056195B (enExample) |
| HU (1) | HUP0300745A3 (enExample) |
| IL (1) | IL154009A0 (enExample) |
| MX (1) | MXPA03000554A (enExample) |
| NO (1) | NO20030219L (enExample) |
| NZ (1) | NZ523683A (enExample) |
| PL (1) | PL365385A1 (enExample) |
| PT (1) | PT1301614E (enExample) |
| WO (1) | WO2002008435A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305699B1 (de) | 2001-06-05 | 2014-08-13 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose |
| EP1427443A4 (en) * | 2001-08-23 | 2006-03-08 | Merck & Co Inc | VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| WO2003068933A2 (en) * | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| RU2356943C2 (ru) | 2003-03-24 | 2009-05-27 | Мерк Энд Ко., Инк. | Молекула нуклеиновой кислоты, кодирующая hpv31 l1, экспрессирующий вектор, клетка-хозяин, вирусоподобная частица и способ ее получения, вакцина, фармацевтическая композиция и способы с их использованием |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
| MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| DE602005020913D1 (de) | 2004-03-24 | 2010-06-10 | Merck Sharp & Dohme | Optimierte expression von hpv-52-l1 in hefe |
| GB0617387D0 (en) * | 2006-09-04 | 2006-10-11 | Glaxo Group Ltd | Synthetic gene |
| EP2099486A2 (en) * | 2006-11-30 | 2009-09-16 | Government Of The United States Of America, As Represented by the Secretary | Codon modified immunogenic compositions and methods of use |
| GB0700914D0 (en) * | 2007-01-18 | 2007-02-28 | Animal Health Inst | Polynucleotides and uses thereof |
| AU2008209759B2 (en) | 2007-01-30 | 2013-03-21 | Transgene S.A. | Papillomavirus E2 polypeptide used for vaccination |
| EP3431099B1 (en) | 2007-03-30 | 2024-01-03 | The Research Foundation for The State University of New York | Attenuated viruses useful for vaccines |
| GB0710538D0 (en) * | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Vaccine |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| TN2018000152A1 (en) | 2015-10-22 | 2019-10-04 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP3364982A4 (en) | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| EP3368051A4 (en) | 2015-10-30 | 2019-06-26 | Children's National Medical Center | GENERATION OF HPV ANTIGEN-SPECIFIC T CELLS FROM A NAIVEN T CELL POPULATION |
| EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
| US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464936A (en) * | 1990-12-21 | 1995-11-07 | Cetus Oncology Corporation | Compositions for identification of papillomavirus replication inhibitors |
| DE4123760C2 (de) * | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
| EP0969862B1 (en) * | 1997-02-07 | 2006-10-18 | Merck & Co., Inc. | Synthetic hiv gag genes |
| JP2002524078A (ja) * | 1998-09-04 | 2002-08-06 | アヴェンティス パスツール リミテット゛ | 子宮頸がんの治療 |
| JP4799789B2 (ja) * | 1999-08-25 | 2011-10-26 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子 |
-
2001
- 2001-07-20 DE DE60124918T patent/DE60124918T2/de not_active Expired - Fee Related
- 2001-07-20 IL IL15400901A patent/IL154009A0/xx unknown
- 2001-07-20 JP JP2002513918A patent/JP2004504057A/ja active Pending
- 2001-07-20 KR KR1020037000847A patent/KR100874552B1/ko not_active Expired - Fee Related
- 2001-07-20 AT AT01953199T patent/ATE346947T1/de not_active IP Right Cessation
- 2001-07-20 DK DK01953199T patent/DK1301614T3/da active
- 2001-07-20 CA CA002416488A patent/CA2416488A1/en not_active Abandoned
- 2001-07-20 CZ CZ2003180A patent/CZ2003180A3/cs unknown
- 2001-07-20 BR BR0112637-7A patent/BR0112637A/pt not_active Application Discontinuation
- 2001-07-20 ES ES01953199T patent/ES2277605T3/es not_active Expired - Lifetime
- 2001-07-20 MX MXPA03000554A patent/MXPA03000554A/es active IP Right Grant
- 2001-07-20 NZ NZ523683A patent/NZ523683A/en unknown
- 2001-07-20 PT PT01953199T patent/PT1301614E/pt unknown
- 2001-07-20 HU HU0300745A patent/HUP0300745A3/hu unknown
- 2001-07-20 AU AU7569501A patent/AU7569501A/xx active Pending
- 2001-07-20 WO PCT/GB2001/003290 patent/WO2002008435A1/en not_active Ceased
- 2001-07-20 PL PL01365385A patent/PL365385A1/xx unknown
- 2001-07-20 CN CNB018161081A patent/CN1262665C/zh not_active Expired - Fee Related
- 2001-07-20 AU AU2001275695A patent/AU2001275695B9/en not_active Ceased
- 2001-07-20 EP EP01953199A patent/EP1301614B1/en not_active Expired - Lifetime
- 2001-07-20 HK HK03106686.3A patent/HK1056195B/en not_active IP Right Cessation
-
2003
- 2003-01-16 NO NO20030219A patent/NO20030219L/no not_active Application Discontinuation
-
2007
- 2007-02-21 CY CY20071100246T patent/CY1106334T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2277605T3 (es) | 2007-07-16 |
| KR100874552B1 (ko) | 2008-12-16 |
| NZ523683A (en) | 2004-08-27 |
| AU7569501A (en) | 2002-02-05 |
| BR0112637A (pt) | 2003-06-10 |
| CN1262665C (zh) | 2006-07-05 |
| PL365385A1 (en) | 2005-01-10 |
| AU2001275695B9 (en) | 2005-05-26 |
| MXPA03000554A (es) | 2004-12-13 |
| DK1301614T3 (da) | 2007-04-02 |
| IL154009A0 (en) | 2003-07-31 |
| PT1301614E (pt) | 2007-02-28 |
| HUP0300745A3 (en) | 2010-01-28 |
| EP1301614A1 (en) | 2003-04-16 |
| WO2002008435A8 (en) | 2002-04-04 |
| JP2004504057A (ja) | 2004-02-12 |
| NO20030219L (no) | 2003-03-20 |
| NO20030219D0 (no) | 2003-01-16 |
| DE60124918T2 (de) | 2007-08-02 |
| CY1106334T1 (el) | 2011-10-12 |
| EP1301614B1 (en) | 2006-11-29 |
| CZ2003180A3 (cs) | 2003-08-13 |
| HUP0300745A2 (hu) | 2003-08-28 |
| CA2416488A1 (en) | 2002-01-31 |
| ATE346947T1 (de) | 2006-12-15 |
| KR20030074586A (ko) | 2003-09-19 |
| CN1462309A (zh) | 2003-12-17 |
| DE60124918D1 (de) | 2007-01-11 |
| HK1056195A1 (en) | 2004-02-06 |
| WO2002008435A1 (en) | 2002-01-31 |
| AU2001275695B2 (en) | 2005-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1301614B1 (en) | Codon-optimized papilloma virus sequences | |
| AU2001275695A1 (en) | Codon-optimized papilloma virus sequences | |
| US7132262B2 (en) | Papilloma virus sequences | |
| US9993542B2 (en) | Compositions and uses therefor | |
| EP1556513B1 (en) | Compositions and methods for treating human papillomavirus-mediated disease | |
| US20070264283A1 (en) | Vaccine | |
| AU2002248978A1 (en) | Novel compositions and uses therefor | |
| WO2013083287A1 (en) | Hpv derived polynucleic acids for therapy | |
| RU2312896C2 (ru) | Последовательность нуклеиновой кислоты, кодирующая белок gag вич-1, способ получения указанной последовательности, вектор, содержащий ее, белок, кодируемый ею, фармацевтическая композиция и их применение для профилактики и/или лечения вич-инфекции и спида | |
| US20130017572A1 (en) | Codon modified polynucleotide sequences for enhanced expression in a host system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20100720 |